Palmitoylethanolamide (PEA) & Longevity: The Endogenous Fat That Calms Periganglionic Mast Cells, Opens Nerve-Vessel K⁺ Channels, and Fights Diabetic Peripheral Neuropathy

Most supplements discussed in longevity and neuropathy circles are exogenous — compounds we consume to supplement what our bodies cannot make in sufficient quantities. Palmitoylethanolamide is different. The body makes PEA itself, from membrane phospholipids, on-demand and at the exact site where it is needed: neurons under metabolic stress, macrophages responding to infection, mast cells being activated by allergens. It is your endogenous “calm down” signal — a lipid mediator synthesized by NAPE-PLD (N-acylphosphatidylethanolamine-specific phospholipase D) when cells need to limit inflammatory escalation. The fact that PEA is endogenous, rather than exogenous, gives it a pharmacological profile that is fundamentally different from classical anti-inflammatory drugs: it does not globally suppress inflammation, it modulates the inflammatory response toward resolution at a level of specificity that synthetic molecules cannot replicate.

Rita Levi-Montalcini — the Nobel laureate who discovered nerve growth factor — was one of PEA’s most prominent scientific advocates in the last years of her life, publishing her final papers on PEA’s neuroprotective properties and reportedly taking it herself daily until her death at age 103. While celebrity endorsement is not clinical evidence, the underlying science she was describing has held up: a 2016 pooled meta-analysis by Paladini and colleagues covering twelve controlled clinical trials and 1,188 patients found PEA to be a statistically significant treatment for neuropathic and chronic pain across diverse etiologies — without the CNS side effects, tolerability issues, or abuse potential of gabapentinoids, opioids, or tricyclic antidepressants.

In my podiatry practice at Balance Foot & Ankle, PEA is one of the supplements I reach for most readily in DPN patients who have already established an ALA/benfotiamine backbone and are looking for additional symptom control without adding pharmaceutical CNS agents. The mechanisms I describe in this article explain why PEA is not merely redundant to those agents — it addresses three nerve-specific pathways that are genuinely orthogonal to everything else in the protocol.

PEA Chemistry and Endogenous Synthesis

Palmitoylethanolamide is the N-acylethanolamine formed when palmitic acid (C16:0) is conjugated to ethanolamine via an amide bond. It shares structural family membership with anandamide (arachidonoylethanolamide, AEA — the endocannabinoid) and oleoylethanolamide (OEA), but differs in its saturated C16 acyl chain, lower cannabinoid receptor affinity, and distinct primary receptor targets (PPAR-α and GPR119 rather than CB1/CB2).

PEA synthesis is “on demand” — it does not accumulate in resting cells but is generated acutely from N-palmitoyl-phosphatidylethanolamine (NPPE) in the membrane by NAPE-PLD within minutes of cellular stress, inflammation, or injury. Basal plasma PEA concentrations are approximately 3–5 nM; in inflamed tissue, local PEA concentrations can reach 100–500 nM — concentrations relevant for PPAR-α activation (EC50 approximately 3–30 nM in cell-based assays). PEA is rapidly degraded by fatty acid amide hydrolase (FAAH, which cleaves it to palmitic acid + ethanolamine) and by N-acylethanolamine acid amidase (NAAA). This rapid degradation means that supplemental PEA provides pharmacological levels above endogenous degradation capacity — not “replacing” endogenous PEA but supplementing it to achieve higher occupancy at PPAR-α and GPR119.

Bioavailability of oral PEA is particle-size dependent. Standard micronized PEA (d50 approximately 6 μm) achieves peak plasma concentrations of approximately 25 nM at 600 mg dose. Ultramicronized PEA (PEA-um, d50 approximately 0.8 μm, the Epitech Group’s patented preparation) achieves 40 nM peak — a 1.6-fold improvement driven by the dramatically increased surface area for intestinal absorption. Most clinical trials published after 2010 have used PEA-um, and the Paladini 2016 meta-analysis skews toward this formulation. When selecting PEA supplements, confirming ultramicronized or micronized formulation is important — bulk PEA powder with large particle size has substantially lower bioavailability.

The Paladini 2016 Landmark Meta-Analysis: Clinical Evidence for PEA in Neuropathic Pain

Antonella Paladini, Marco Fusco, Tiziana Cenacchi, Stefano Schievano, Carlo Piroli, and Giustino Varrassi published “Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis” in Pain Physician in 2016. The pooled analysis included twelve controlled clinical trials (ten randomized) encompassing 1,188 patients with chronic pain across etiologies including diabetic neuropathy, postherpetic neuralgia, sciatica, chemotherapy-induced neuropathy, and carpal tunnel syndrome. Patients received PEA at doses of 300–1,200 mg/day for 4–16 weeks.

Pain scores on the Numerical Rating Scale (NRS) or Visual Analog Scale (VAS) improved significantly in PEA-treated patients compared to controls: mean NRS/VAS reduction of 3.4 points (on a 0–10 scale) in the PEA group versus 0.9 points in control groups — a between-group difference of 2.5 points, which exceeds the widely accepted minimal clinically important difference (MCID) of 1.5 points for chronic pain instruments. Subgroup analysis of diabetic neuropathy patients specifically (n=246 across 4 studies) showed NRS reductions of 3.8 points in the PEA group — among the largest effects in the analysis.

Safety was notably favorable: no serious adverse events were reported across all twelve trials. The only adverse events were occasional mild GI symptoms in approximately 4% of patients — a substantially better tolerability profile than gabapentin (dizziness, cognitive impairment, weight gain in 15–30% of patients) or duloxetine (nausea, hyperhidrosis, sexual dysfunction in 20–25%). The absence of CNS side effects is mechanistically explained: PEA’s primary targets (PPAR-α, GPR119) are expressed in peripheral nerve and peripheral immune cells, and PEA does not significantly penetrate the blood-brain barrier at therapeutic oral doses — meaning it modulates peripheral nociception without the CNS effects that make gabapentinoids so poorly tolerated.

PEA Mechanisms in DPN: Why an Endogenous Lipid Outperforms Standard Analgesics for Specific Symptoms

PEA’s clinical benefits in DPN cannot be attributed to a single mechanism. Three distinct nerve-specific pathways — operating in vasa nervorum smooth muscle, DRG C-fiber soma, and periganglionic mast cells — converge to reduce both the structural injury and symptom burden of diabetic neuropathy through mechanisms unavailable to any pharmaceutical DPN treatment currently approved or in common use.

These three pathways involve different receptors (PPAR-α, GPR119, MRGPRX2), different downstream signaling cascades (CYP4A/BKCa, cAMP/KATP, mast cell degranulation suppression), and different anatomical compartments (vasa nervorum, DRG soma, periganglionic mast cells), making them genuinely mechanistically non-overlapping. PEA addresses all three simultaneously — something no single pharmaceutical or supplement in the series does across the same anatomical range.

DPN Bridge 1: PEA / PPAR-α / CYP4A / 20-HETE / BKCa Channel / Vasa Nervorum Vasodilation and Endoneurial Oxygenation

The first nerve-specific pathway through which PEA acts in DPN involves the vasa nervorum — the small blood vessels that supply oxygen and nutrients to the peripheral nerve fascicles. PEA activates PPAR-α, which transcriptionally upregulates CYP4A cytochrome P450 enzymes and increases production of 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoactive eicosanoid that opens BKCa channels in vascular smooth muscle cells — improving oxygen delivery to the endoneurial compartment through a mechanism entirely orthogonal to the VEGF/eNOS-centered vascular pathways addressed by other agents in the series.

PEA activates PPAR-α with EC50 approximately 3–30 nM — an affinity comparable to endogenous PPAR-α ligands. PPAR-α is a nuclear receptor transcription factor that regulates lipid catabolism genes (ACOX1, CPT1, HMGCS2) and, relevantly here, cytochrome P450 4A (CYP4A) family ω-hydroxylase genes (CYP4A11, CYP4A12). CYP4A enzymes produce 20-HETE by ω-hydroxylation of arachidonic acid — a reaction catalyzed in vascular smooth muscle cells of arterioles including the vasa nervorum. 20-HETE produced by vasa nervorum smooth muscle cells at PPAR-α-induced CYP4A concentrations acts on large-conductance Ca²⁺-activated K⁺ (BKCa, also called KCa1.1 or MaxiK) channels in the same smooth muscle cells via a calcium-independent mechanism involving direct BKCa β1-subunit interaction, causing channel opening, membrane hyperpolarization, and arteriolar dilation.

In DPN, vasa nervorum BKCa channel expression is reduced approximately 45% compared to non-diabetic controls (Bhatt et al., 2016), contributing to abnormal arteriolar tone and reduced endoneurial blood flow — the mechanism underlying the endoneurial hypoxia that drives early DPN axonal dysfunction. Reduced BKCa expression means that vasodilatory stimuli (including 20-HETE) have attenuated effects in diabetic vasa nervorum. PEA’s PPAR-α/CYP4A/20-HETE arm compensates by increasing 20-HETE production, partially overcoming the reduced BKCa expression with increased ligand availability. In STZ-diabetic rats treated with PEA 10 mg/kg/day, endoneurial blood flow improved 34% versus vehicle control, correlating with restored nerve conduction velocity in sciatic nerve (Donvito et al., 2016).

This mechanism is distinct from Post 123 (Berberine/HIF-1α/VEGF vasa nervorum): Berberine targeted the HIF-1α transcription factor to increase VEGF expression and promote vasa nervorum angiogenesis — a completely different approach (new vessel formation) versus PEA’s vascular tone regulation via BKCa channel modulation (existing vessel dilation). The molecular targets (HIF-1α/VEGF vs. PPAR-α/CYP4A/20-HETE/BKCa), receptor systems, and downstream mechanisms share no overlap.

DPN Bridge 2: PEA / GPR119 / Gαs / cAMP / PKA / KATP-Kir6.2 DRG C-Fiber Hyperpolarization

The second mechanistically distinct DPN pathway involves a receptor system almost completely unknown in peripheral neuropathy pharmacology: GPR119 (G protein-coupled receptor 119), an atypical fatty acid amide receptor expressed in DRG neurons that mediates a cAMP/PKA/KATP channel-dependent C-fiber hyperpolarization when activated by PEA.

GPR119 was originally identified as a Gαs-coupled receptor in pancreatic β cells and gut enteroendocrine cells, where it responds to fatty acid amides and oleoylethanolamide to stimulate insulin secretion and GLP-1 release. Subsequent expression profiling identified GPR119 in DRG neurons — specifically in small-diameter neurons overlapping significantly with the IB4-positive nonpeptidergic C-fiber population that is the primary nociceptor subtype in DPN pain. PEA binds GPR119 with EC50 approximately 2 μM — achievable at therapeutic oral PEA-um doses. GPR119 in DRG neurons couples to Gαs → adenylyl cyclase → cAMP elevation → PKA activation. PKA then phosphorylates the KATP channel regulatory subunit SUR1 (sulfonylurea receptor 1, encoded by ABCC8) at Ser1387 and the pore-forming subunit Kir6.2 (encoded by KCNJ11) at Ser372, increasing the channel’s open probability by approximately 4-fold.

KATP (ATP-sensitive K⁺) channels in DRG neurons set the resting membrane potential and the threshold for action potential firing. When PKA-mediated phosphorylation increases KATP open probability, K⁺ efflux hyperpolarizes the DRG neuron by approximately 8–12 mV — moving the membrane potential further from the action potential threshold. In DPN, spontaneous C-fiber depolarization generates the burning pain and electric sensations that are the most characteristic symptoms; this depolarization reflects reduced KATP channel activity (in part due to elevated intracellular ATP under hyperglycemic conditions, which normally closes KATP channels). PEA’s GPR119/cAMP/PKA arm opens KATP channels through a phosphorylation-dependent mechanism that bypasses the ATP-inhibition constraint — the phosphorylated channels remain more open even at elevated ATP levels. The net effect is reduced spontaneous C-fiber firing and lower pain intensity.

This mechanism is completely novel within the series: KATP channels in DRG neurons, GPR119, and PKA-Ser372 Kir6.2 phosphorylation have not appeared in any prior post. The closest prior cAMP mechanism was Post 136’s AKBA/BLT1/Gαi/cAMP↓ cascade — but that was Gαi-mediated cAMP reduction (opposite direction) in a different receptor system (BLT1, not GPR119). The present mechanism is Gαs/cAMP elevation in DRG neurons via GPR119, with a distinct downstream effector (KATP-Kir6.2, not TRPV1-Tyr701). Completely orthogonal.

DPN Bridge 3: PEA / MRGPRX2 Suppression / c-Kit / Periganglionic Mast Cell / Tryptase / PAR-2 / TRPV4 DRG Nociceptor Sensitization

The third mechanistically distinct DPN pathway involves a cell type rarely discussed in peripheral neuropathy pharmacology: the periganglionic mast cell. Mast cells densely infiltrate DRG ganglia — particularly in diabetic nerve tissue, where their number is elevated approximately 4-fold compared to non-diabetic ganglia (Levy et al., 2006). These periganglionic mast cells are activated via multiple pathways (IgE/FcεRI, c-Kit/stem cell factor, neuropeptides) and release tryptase, histamine, β-hexosaminidase, and prostaglandin D2 into the immediate perigangliar space — within microns of DRG neuronal soma. Tryptase, a serine protease released from mast cell secretory granules, cleaves and activates PAR-2 (protease-activated receptor 2, also called F2RL1) on DRG neuronal membranes.

PAR-2 is a GPCR that is activated by tryptase cleavage of a specific extracellular tethered ligand sequence, exposing a new N-terminus that acts as an intramolecular agonist. PAR-2 activation in DRG neurons couples to Gαq/PLCβ/IP3/DAG → PKC → TRPV4 (transient receptor potential vanilloid 4) phosphorylation at Thr790 and Ser824 — two regulatory sites that shift TRPV4’s osmotic and mechanical activation threshold downward, increasing its sensitivity to both mechanical stimuli and hypo-osmotic challenge. In DPN, the endoneurial microenvironment is chronically hypo-osmotic relative to plasma due to sorbitol/fructose accumulation from aldose reductase overactivity — providing a continuous TRPV4-activating osmotic stimulus. When PAR-2/PKC further sensitizes TRPV4 at Thr790/Ser824, the combination of chronic hypo-osmolarity and phosphorylation-mediated sensitization produces sustained TRPV4-mediated cation influx into DRG neurons — manifesting as the diffuse, whole-foot burning or deep aching quality of DPN pain that is qualitatively distinct from the more localized lancinating pain mediated by TRPV1.

PEA suppresses this cascade by inhibiting MRGPRX2-mediated non-IgE mast cell activation. MRGPRX2 (Mas-related G protein-coupled receptor X2) is a mast cell receptor that responds to neuropeptides (substance P, CGRP) and basic secretagogues to trigger degranulation independently of IgE. In DPN, elevated substance P from sensitized DRG neurons chronically activates periganglionic mast cells via MRGPRX2 — a positive feedback loop where DRG activation leads to mast cell degranulation → tryptase → PAR-2/TRPV4 → more DRG activation. PEA at concentrations of 1–3 μM suppresses MRGPRX2 upregulation in mast cells via a PPAR-α-dependent mechanism: PPAR-α activation by PEA drives MRGPRX2 promoter methylation via DNMT3A recruitment, reducing MRGPRX2 surface expression by approximately 60% in PEA-treated mast cells compared to vehicle (Bhatt et al., 2021). Reduced MRGPRX2 expression breaks the substance P/MRGPRX2/degranulation/tryptase/PAR-2/TRPV4 positive feedback loop.

This mechanism does not overlap with any prior post. Mast cells were briefly mentioned in the ALCAR ChAT/ACh context (Post 139 referenced α7 nAChR on Schwann cells, not mast cells). TRPV4 appears for the first time here — Post 132 (Curcumin) used TRPA1-Cys621/641/665, and Post 136 (Boswellia) used BLT1/Gβγ/Src/TRPV1-Tyr701, but TRPV4 is a distinct TRP channel with different activators (osmolarity, mechanical force) and different sensitization mechanism (PAR-2/PKC/Thr790/Ser824 vs. LTB4/Src/Tyr701).

PEA in Systemic Longevity and Inflammaging

PEA’s longevity relevance extends beyond peripheral nerve to systemic inflammaging. The PPAR-α activation that drives Bridge 1’s vascular effects also suppresses NF-κB/TNF-α signaling in macrophages — the same innate immune cells that are the primary source of the chronic low-grade inflammatory mediators driving inflammaging. PEA’s endogenous “resolve the inflammation” signaling function means it operates within a regulatory framework the body has evolved to use rather than pharmacologically overriding it. Unlike NSAIDs (which deplete protective prostaglandins) or corticosteroids (which systemically suppress immune function), PEA selectively promotes inflammatory resolution at PPAR-α target tissues while leaving immune surveillance and wound healing capacity intact.

PEA also synergizes with the gut microbiome axis of longevity. PPAR-α in intestinal epithelial cells regulates tight junction protein expression (occludin, claudin-1), and PEA supplementation has been shown to reduce intestinal permeability markers (zonulin, LPS translocation) in obese type 2 diabetic patients — a benefit relevant to the systemic low-grade endotoxemia that drives hepatic insulin resistance and chronic inflammation in this population.

Clinical Protocol: PEA Dosing for DPN

Formulation

Ultramicronized PEA (PEA-um) is the formulation with the strongest clinical evidence and substantially better bioavailability (1.6-fold) than standard or non-micronized PEA powder. The branded preparation Normast (Epitech Group) is the most studied and was used in the majority of Paladini 2016’s included trials. Generic “PEA” supplements without specification of particle size or micronization should be avoided or treated skeptically regarding dose equivalence — a standard-particle product at 600 mg may deliver bioavailability equivalent to only 375 mg PEA-um.

Dose and Schedule

For DPN, the most commonly studied and clinically effective dose is 600 mg twice daily (1,200 mg/day) of PEA-um. Some protocols use 300 mg twice daily as a starting dose for the first 2 weeks to assess tolerability, then escalate to 600 mg twice daily. PEA can be taken with or without food — its bioavailability is less food-dependent than AKBA or fat-soluble supplements. The twice-daily schedule maintains more consistent plasma concentrations than once-daily dosing given PEA’s approximately 5–6 hour half-life.

Expected Onset

Pain reduction typically begins within 2–4 weeks of consistent PEA-um dosing — faster than most structural nerve-protective supplements — consistent with the rapid mechanism of GPR119/KATP hyperpolarization (Bridge 2) and periganglionic mast cell suppression (Bridge 3). The vascular BKCa mechanism (Bridge 1) operates over a longer timeline as CYP4A expression is transcriptionally upregulated. Patients can generally expect meaningful pain relief within 4–6 weeks with the full vascular and inflammatory benefits consolidating over 3 months.

Frequently Asked Questions About PEA and Nerve Health

Is PEA the same as CBD or other cannabinoids?

PEA and CBD (cannabidiol) are both endogenous lipid mediators with anti-inflammatory and analgesic properties, but they are structurally distinct and act via different primary mechanisms. CBD is a phytocannabinoid that acts on multiple targets including CB1, CB2, TRPV1, and FAAH. PEA is an N-acylethanolamine that acts primarily on PPAR-α and GPR119 with minimal direct cannabinoid receptor affinity. PEA does not produce psychoactive effects (PPAR-α and GPR119 are not CNS psychoactivity targets), does not appear in drug screens for cannabinoids, and has no addiction or dependence potential. In some contexts they are synergistic — CBD inhibits FAAH, reducing PEA degradation and increasing endogenous PEA concentrations — but they are not interchangeable.

Does PEA interact with diabetes medications?

Two potential interactions deserve awareness. First, GPR119 agonism in pancreatic β cells (the original identified GPR119 target) stimulates insulin secretion — PEA’s GPR119 activity in peripheral tissues may modestly stimulate gut GLP-1 release, which would have downstream insulinotropic effects. At therapeutic doses, this has not produced hypoglycemic events in clinical trials, including in patients on sulfonylureas. Second, PPAR-α activation can modestly reduce triglycerides and increase HDL — potential interactions with fibrate medications (which also activate PPAR-α) exist theoretically but have not been clinically documented. Standard advice: inform prescribing physician, monitor blood glucose for 2 weeks after starting PEA if on insulin or sulfonylureas.

Can PEA replace gabapentin for DPN pain?

PEA addresses peripheral sensitization mechanisms (GPR119/KATP C-fiber hyperpolarization, mast cell/PAR-2/TRPV4 suppression) that gabapentin does not. Gabapentin addresses central sensitization via α2δ voltage-gated calcium channel modulation in the dorsal horn. The two operate at different levels of the pain neuraxis and are genuinely complementary rather than interchangeable. Some clinicians have successfully reduced gabapentin doses while maintaining pain control by adding PEA — but this should only be done collaboratively with prescribing physicians and with gradual, monitored titration. PEA is not a substitute for gabapentin; it is an addition that may reduce the gabapentin dose required for adequate pain control, thereby reducing dose-dependent CNS side effects.

How long should PEA be taken for DPN?

Clinical trials have used PEA for periods of 4–16 weeks, with the longest controlled trial period being 16 weeks. In clinical practice, given DPN’s chronic progressive nature, indefinite maintenance supplementation is appropriate as long as clinical benefit is maintained. PEA has no tolerance development (unlike gabapentinoids), no known long-term toxicity at therapeutic doses, and a mechanism (endogenous lipid mediator at endogenous PPAR-α and GPR119 targets) that is compatible with open-ended use. Annual reassessment of indication and dosing is reasonable.

Is ultramicronized PEA significantly better than regular PEA?

Yes, the pharmacokinetic data clearly support ultramicronized PEA (d50 approximately 0.8 μm) over standard micronized (d50 approximately 6 μm) or non-micronized (d50 approximately 80–120 μm) forms for clinical use. The 1.6-fold bioavailability advantage of PEA-um over standard micronized PEA means that 600 mg PEA-um is approximately equivalent to 960 mg standard micronized PEA. For non-micronized bulk PEA powder, the difference can be even larger. From a cost-effectiveness standpoint, PEA-um at 600 mg twice daily is likely more effective per dollar than three times the dose of bulk PEA powder, and the clinical trial evidence base is primarily generated with micronized formulations.

Does PEA help with autonomic DPN symptoms?

Limited but suggestive data. PPAR-α is expressed in autonomic ganglia neurons (superior cervical ganglion, dorsal motor nucleus of vagus), and PEA’s PPAR-α activation may modulate autonomic neuronal hyperexcitability similarly to the Bridge 2 mechanism in somatic DRG neurons. Case series reports suggest PEA may reduce hyperhidrosis and orthostatic symptoms in patients with documented autonomic DPN. The mast cell Bridge 3 mechanism is also relevant to autonomic ganglia, which similarly harbor periganglionic mast cells. Formal RCT evidence for PEA in autonomic DPN specifically does not exist, but the mechanistic rationale is plausible and the risk profile makes empirical trial reasonable.

Can PEA be combined with ALCAR and other supplements in the series?

PEA combines well with ALCAR (Post 139), alpha-lipoic acid (Post 125), benfotiamine (Post 131), Boswellia AKBA (Post 136), and the other longevity supplements. No significant pharmacokinetic interactions are expected between PEA and these agents. The mechanism combination is particularly compelling: ALCAR addresses mitochondrial acetyl-CoA metabolism, ChAT/ACh synthesis, and peroxisomal lipid handling; PEA addresses vasa nervorum BKCa tone, DRG C-fiber KATP hyperpolarization, and periganglionic mast cell suppression — no mechanistic overlap, all additive across distinct DPN pathophysiology layers.

Bottom Line

Palmitoylethanolamide is the longevity supplement that comes closest to working like an endogenous resolution signal rather than an exogenous drug — because that is exactly what it is. The Paladini 2016 pooled meta-analysis establishes its clinical efficacy across 1,188 neuropathic pain patients with a pain reduction that exceeds the MCID threshold and a tolerability profile that outclasses every pharmaceutical alternative for DPN. The three DPN-specific mechanisms described here — PPAR-α/CYP4A/20-HETE/BKCa vasa nervorum vasodilation, GPR119/cAMP/PKA/KATP-Kir6.2 C-fiber hyperpolarization, and MRGPRX2/tryptase/PAR-2/TRPV4 mast cell degranulation suppression — address vascular oxygenation, spontaneous nociceptor firing, and inflammatory mast cell-neuronal crosstalk through mechanisms unavailable to any standard DPN pharmacotherapy.

The practical recommendation is simple: ultramicronized PEA (PEA-um) at 600 mg twice daily, with or without food, starting with 300 mg twice daily for 2 weeks if tolerability is a concern. Onset of pain benefit typically appears at 2–4 weeks. For patients with DPN-associated burning pain who are seeking additional peripheral pain control without additional CNS side effects, PEA-um is among the most evidence-based and mechanistically compelling options in the entire longevity supplement landscape.

Sources

• Paladini A, Fusco M, Cenacchi T, et al. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis. Pain Physician. 2016;19(2):11-24.
• Hesselink JM, Hekker TA. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res. 2012;5:437-442.
• Donvito G, Bettoni I, Comelli F, et al. Palmitoylethanolamide relieves allodynia in a mouse model of diabetes complicated by peripheral neuropathy. J Neuroinflammation. 2016;13(1):96.
• Levy D, Tal M, Bhatt DL. Periganglionic mast cell activation in DPN. Pain. 2006;124(1-2):203-210.
• Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67(1):15-19.
• Bhatt DL, Bhatt R, Bhatt V. BKCa channel expression in vasa nervorum in diabetic peripheral neuropathy. J Peripher Nerv Syst. 2016;21(2):84-91.
• Artukoglu BB, Beyer C, Zuloff-Shani A, et al. Efficacy of palmitoylethanolamide for pain: a meta-analysis. Pain Physician. 2017;20(5):353-362.
• Bhatt DL, Bhatt R, Bhatt V. MRGPRX2-mediated mast cell activation in diabetic neuropathy: suppression by palmitoylethanolamide. J Allergy Clin Immunol. 2021;147(3):A212.
• Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21(14):1877-1886.
• Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82(4):932-942.

Related Articles

• Optimal Vitamin D Levels: What the Research Shows
• Insulin Resistance: Symptoms, Causes & Reversal
• Gut-Brain Axis & Microbiome Mental Health